Scancell’s Cancer Vaccine Supercharges Melanoma Immunotherapy in Recent Trials

Scancell's DNA cancer vaccines, SCIB1 and iSCIB1+, were tested with checkpoint inhibitors (nivolumab and ipilimumab) in the Phase 2 SCOPE trial for late-stage melanoma patients3.

The combination of SCIB1/iSCIB1+ plus checkpoint inhibitors achieved an overall response rate (ORR) of 68.6% and a complete response (CR) rate of 17.9%, with a disease control rate (DCR) of 88% among evaluable patients3.

The vaccine is designed as an "off-the-shelf," non-personalized DNA therapy, delivered using a needle-free device, and aims to generate potent T-cell responses against melanoma tumors24.

The British National Health Service (NHS) is fast-tracking access to Scancell's iSCIB1+ vaccine as part of the NHS Cancer Launch Pad innovation initiative, with expanded patient access and integration into the ongoing SCOPE Phase II trial4.

Scancell’s approach demonstrated positive efficacy, durability, immune responses, and safety profile in melanoma immunotherapy when combined with checkpoint inhibitors, supporting potential future regulatory discussions for accelerated approval3.

Sources:

2. https://www.youtube.com/watch?v=TodDgfpBjjA

3. https://www.cancernetwork.com/view/novel-cancer-vaccine-combos-show-efficacy-safety-in-late-stage-melanoma

4. https://www.pharmaceutical-technology.com/news/scancell-shares-up-6-after-nhs-partnership-for-fast-track-cancer-vaccine-trial/